Melior Discovery Selected as Preclinical CRO to Support Linnaeus Therapeutics' ARPA-H PROSPR Program

PartnershipLNS8801Positive

AI Analysis

Summary

Melior Discovery selected as preclinical CRO by Linnaeus Therapeutics to conduct in vivo pharmacology studies for LNS8801 development under ARPA-H PROSPR funding for healthspan preservation.

Importance:3/10

Sentiment:

0.30

preclinicalCROpartnershipARPA-HPROSPRin vivo pharmacology

Read the original article

Published by PR Newswire Clinical Trials on July 21, 2026 1:00 PM

Read Original